<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3693">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04406688</url>
  </required_header>
  <id_info>
    <org_study_id>04-AnIt-20</org_study_id>
    <nct_id>NCT04406688</nct_id>
  </id_info>
  <brief_title>Prediction of Acute Kidney Injury in Patients With COVID-19</brief_title>
  <official_title>Prediction of Acute Kidney Injury in Patients With COVID-19 Associated Acute Respiratory Distress Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Muenster</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Muenster</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The two biomarkers determined in urine, &quot;Tissue Inhibitor of Metalloproteinases 2 (TIMP-2)&quot;&#xD;
      and &quot;Insulin-like Growth Factor-Binding Protein 7 (IGFBP7)&quot;, can indicate the occurrence of&#xD;
      Acute kidney injury (AKI) in cardiac surgery and critically ill patients at an early stage.&#xD;
      However, no data are available whether these parameters can also predict the occurrence of&#xD;
      AKI in the context of COVID-19 infection. An early prediction of AKI can be helpful for the&#xD;
      optimisation of therapeutic management to improve patient outcome and for the triage of&#xD;
      patients.&#xD;
&#xD;
      The aim of this observational study is to evaluate whether the biomarker [TIMP- 2]*[IGFBP7]&#xD;
      can predict the occurrence of AKI in critically ill patients suffering from SARS-CoV2&#xD;
      associated acute respiratory distress syndrome.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is rapidly spreading around the&#xD;
      world. The current outbreak of infections with SARS-CoV-2 is termed Coronavirus Disease 2019&#xD;
      (COVID-19). Two other coronavirus infections, SARS in 2002-2003 and Middle East Respiratory&#xD;
      Syndrome (MERS) in 2012, both caused severe respiratory syndrome in humans. All 3 of these&#xD;
      emerging infectious diseases are caused by β-coronaviruses.&#xD;
&#xD;
      Although COVID-19 primarily affects the lungs and may cause severe hypoxemia, other organs&#xD;
      including the GI tract, heart and kidney are affected. Acute kidney injury secondary to&#xD;
      COVID-19 (COV-AKI) is reported to occur in about 15-25% of patients hospitalized with&#xD;
      COVID-19 infection. The majority of AKI cases are mild to moderate with renal replacement&#xD;
      requirement in about 25%. However, AKI was much more common in non-survivors (&gt;50%). Although&#xD;
      kidney failure appears to occur late in the course, patients may begin to develop AKI within&#xD;
      the first 3 days of hospitalization. Similar to AKI in other settings,3 COV-AKI is likely to&#xD;
      be of variable etiology. Thus, there may be a long window for treatment.&#xD;
&#xD;
      The two cell-cycle arrest markers, tissue inhibitor of metalloproteinases-2 (TIMP-2) and&#xD;
      insulin-like growth-factor binding protein 7 (IGFBP7), have been shown to early predict the&#xD;
      occurrence of AKI in cardiac surgical and critically ill patients. However, there is no data&#xD;
      available whether (TIMP-2)*(IGFBP7) can predict the occurrence of AKI in the COVID19 setting.&#xD;
      Early prediction of AKI may be valuable to optimize therapeutic management in order to&#xD;
      improve patient's outcome and might be helpful to triage patients.&#xD;
&#xD;
      The goal of this observational trial is to evaluate whether (TIMP-2)*(IGFBP7) early predicts&#xD;
      the occurrence of AKI in critically ill patients with SARS-CoV2 associated ARDS.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 22, 2020</start_date>
  <completion_date type="Anticipated">March 2021</completion_date>
  <primary_completion_date type="Anticipated">February 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Occurence of acute kidney injury (AKI)</measure>
    <time_frame>within 7 days after beginning of moderate or severe ARDS</time_frame>
    <description>Occurence of moderate or severe AKI</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Occurence of transient and persistent AKI</measure>
    <time_frame>within 7 days after beginning of moderate or severe ARDS</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurence of Renal replacement therapy during hospital stay</measure>
    <time_frame>up to 4 weeks after beginning of moderate or severe ARDS</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of renal replacement therapy</measure>
    <time_frame>up to 4 weeks after beginning of moderate or severe ARDS</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>up to 4 weeks after beginning of moderate or severe ARDS</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of mechanical ventilation</measure>
    <time_frame>up to 4 weeks after beginning of moderate or severe ARDS</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of vasopressor administration</measure>
    <time_frame>up to 4 weeks after beginning of moderate or severe ARDS</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU length of stay</measure>
    <time_frame>up to 4 weeks after beginning of moderate or severe ARDS</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital length of stay</measure>
    <time_frame>up to 4 weeks after beginning of moderate or severe ARDS</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Concentration of pro- and antiinflammatory mediators</measure>
    <time_frame>within 7 days after beginning of moderate or severe ARDS</time_frame>
    <description>Add-on-Analysis: Concentration of interleukin (IL) 6, IL8</description>
  </other_outcome>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Acute Kidney Injury</condition>
  <condition>COVID-19</condition>
  <condition>ARDS</condition>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      EDTA plasma, urine&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Primary care clinic&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Moderate or severe ARDS according to the Berlin definition&#xD;
&#xD;
          2. SARS-CoV2 positive test&#xD;
&#xD;
          3. Age ≥ 18 years&#xD;
&#xD;
          4. Informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pre-existing AKI&#xD;
&#xD;
          2. Severe CKD with eGFR&lt;20ml/min&#xD;
&#xD;
          3. Chronic dialysis dependency&#xD;
&#xD;
          4. Kidney transplant within the last 12 months&#xD;
&#xD;
          5. Pregnancy, breastfeeding&#xD;
&#xD;
          6. Persons with any kind of dependency on the investigator or employed by the sponsor or&#xD;
             investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexander Zarbock, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital Muenster, Dept. of Anesthesiology, Intensive Care Medicine and Pain Therapy</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alexander Zarbock, MD</last_name>
    <phone>+49-251-8347252</phone>
    <email>aki@anit.uni-muenster.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Melanie Meersch, MD</last_name>
    <email>aki@anit.uni-muenster.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital Münster</name>
      <address>
        <city>Münster</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centro Hospitalar e Universitário de Coimbra</name>
      <address>
        <city>Coimbra</city>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centro Hospitalar e Universitário do Porto</name>
      <address>
        <city>Porto</city>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital de la Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Germans Trias i Pujol</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario de Navarra</name>
      <address>
        <city>Pamplona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Mutua Terrassa</name>
      <address>
        <city>Terrassa</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital la Fe</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Guy's &amp; St. Thomas Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Portugal</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>May 18, 2020</study_first_submitted>
  <study_first_submitted_qc>May 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 28, 2020</study_first_posted>
  <last_update_submitted>January 4, 2021</last_update_submitted>
  <last_update_submitted_qc>January 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>biomarker</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Kidney Injury</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

